Literature DB >> 30609318

Vitamin D3 in children with allergic asthma in clinical practice.

Amelia Licari1, Gian Luigi Marseglia1, Giorgio Ciprandi2.   

Abstract

Asthma is a chronic inflammatory disorder; type 2 inflammation is the most common asthma endotype in childhood. T regulatory cells are functionally and allergen-specifically defective in allergic patients. Vitamin D3 exerts many functions on immune system, mainly concerning T regulatory function. Asthma control is the goal of the asthma treatment. We aimed to stratified a group of 76 consecutive children (50 males, 26 females, mean age 10.4 + 2.2 years) with allergic asthma and visited for the first time at a third-level paediatric clinic during a 3-month period, considering the Vitamin D3 serum levels. The three Vitamin D3 classes were not able to discriminate significant difference for all the parameters considered. In conclusion, Vitamin D3 serum assessment seems to be scarcely useful to pheno/endotyping allergic asthmatic children in clinical practice.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Vitamin D3; asthma; asthma control; clinical practice

Mesh:

Substances:

Year:  2019        PMID: 30609318     DOI: 10.1002/ppul.24229

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

Review 1.  Early Life Risk Factors in Pediatric EoE: Could We Prevent This Modern Disease?

Authors:  Martina Votto; Gian Luigi Marseglia; Maria De Filippo; Ilaria Brambilla; Silvia Maria Elena Caimmi; Amelia Licari
Journal:  Front Pediatr       Date:  2020-05-29       Impact factor: 3.418

2.  Suboptimal Serum 25-Hydroxy-Vitamin D Is Associated with a History of Recent Disease Exacerbation in Pediatric Patients with Bronchial Asthma or Asthma-Suggestive Recurrent Wheezing.

Authors:  Teodora-Irina Adam-Bonci; Paraschiva Cherecheș-Panța; Eduard-Alexandru Bonci; Sorin Claudiu Man; Ancuța Cutaș-Benedec; Tudor Drugan; Raluca Maria Pop; Alexandru Irimie
Journal:  Int J Environ Res Public Health       Date:  2020-09-09       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.